MedTrace Logo

Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients

NCT06051123 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-04-30

No results posted yet for this study

Summary

The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.

Conditions

  • ALSFTD
  • ALS (Amyotrophic Lateral Sclerosis)
  • Frontal Temporal Dementia (FTD)

Interventions

DIETARY_SUPPLEMENT

Probiotic

Participants will be taking 1 sachet a day.

DIETARY_SUPPLEMENT

Placebo

Participants will be taking 1 sachet a day.

Sponsors & Collaborators

  • Lallemand Health Solutions

    collaborator INDUSTRY

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Genevieve Matte, MDCM, FRCP · CRCHUM

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06051123 on ClinicalTrials.gov